TABLE 2.

NNRTI susceptibility in clinical samples containing K101P, K103R, V179D, or K103R plus V179D^a

Mutation(s) (nb)	NVP FC				DLV FC				EFV FC
	Mean	Median	Range	% > 10c	Mean	Median	Range	% > 10	Mean	Median	Range	% > 10
K101P (35)	278	400	21.5-400	100	51	28	2.5-250	83	65	29	5.7-700	94
K103R only (298)	1.0	0.8	0.2-10	0.3	1.2	0.8	0.1-23	0.7	0.8	0.7	0.1-12	0.3
V179D only (171)	2.2	1.4	0.3-27	2.9	5.4	3.8	0.2-42	10	3.3	2.2	0.3-68	3.5
K103R + V179D (41)	72	16	1.2-400	71	67	27	2.1-250	80	35	16	0.9-196	73

^aClinical samples containing the indicated mutations (excluding mixtures) but lacking any known NNRTI resistance mutation (A98G, K101E, K103N/S, V106A/M, P225H, M230L, P236L, or any mutation at position L100, Y181, Y188, G190, or F227) were identified. Samples with IC₅₀s above the highest drug concentration tested in the assay were assigned a maximum FC value based on the ratio of the highest concentration tested to the lowest reference virus IC₅₀ measured over a 1-year period. These values are 400-, 250-, and 700-fold for NVP, DLV, and EFV, respectively. Nucleotide sequences for the RT region of samples with K101P or K103R plus V179D have been submitted to GenBank (accession ID DQ224082-DQ224157).

^bn, no. of samples.

^c% > 10, percent samples for which the FC of the NNRTI was > 10.